4/1
09:00 am
xair
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
Medium
Report
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
3/27
08:36 am
xair
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
Medium
Report
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
3/26
04:23 pm
xair
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO [Yahoo! Finance]
Medium
Report
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO [Yahoo! Finance]
3/26
04:05 pm
xair
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
Medium
Report
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
3/18
08:40 am
xair
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
3/17
05:14 pm
xair
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial [Yahoo! Finance]
Low
Report
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial [Yahoo! Finance]
3/17
04:35 pm
xair
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
Low
Report
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
3/11
07:37 am
xair
Beyond Air to Participate in the 38th Annual Roth Conference in March [Yahoo! Finance]
Low
Report
Beyond Air to Participate in the 38th Annual Roth Conference in March [Yahoo! Finance]
3/11
07:00 am
xair
Beyond Air to Participate in the 38th Annual Roth Conference in March
Low
Report
Beyond Air to Participate in the 38th Annual Roth Conference in March
3/10
11:50 am
xair
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
3/10
08:01 am
xair
Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals [Seeking Alpha]
Medium
Report
Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals [Seeking Alpha]
3/10
07:30 am
xair
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
Medium
Report
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
3/4
05:57 am
xair
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies [Yahoo! Finance]
Low
Report
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies [Yahoo! Finance]
2/25
04:42 pm
xair
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval [Yahoo! Finance]
Medium
Report
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval [Yahoo! Finance]
2/20
08:14 pm
xair
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... [Yahoo! Finance]
2/20
08:00 am
xair
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
Medium
Report
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
2/13
04:46 pm
xair
Beyond Air, Inc. Q3 2026 Earnings Call Summary [Yahoo! Finance]
Low
Report
Beyond Air, Inc. Q3 2026 Earnings Call Summary [Yahoo! Finance]
2/13
10:43 am
xair
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript [Seeking Alpha]
Neutral
Report
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript [Seeking Alpha]
2/13
07:30 am
xair
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Medium
Report
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
2/4
08:00 am
xair
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
Low
Report
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
1/27
06:24 pm
xair
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences [Yahoo! Finance]
Medium
Report
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences [Yahoo! Finance]
1/27
04:05 pm
xair
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
Medium
Report
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
1/26
04:05 pm
xair
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
Medium
Report
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
1/21
08:00 am
xair
Beyond Air (NASDAQ:XAIR) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.
Low
Report
Beyond Air (NASDAQ:XAIR) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.
1/20
08:11 am
xair
Beyond Air (NASDAQ:XAIR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
High
Report
Beyond Air (NASDAQ:XAIR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.